ID   KKU-100
AC   CVCL_3996
SY   KKU100; K100
DR   BTO; BTO:0003934
DR   cancercelllines; CVCL_3996
DR   Cell_Model_Passport; SIDM01579
DR   DepMap; ACH-001536
DR   JCRB; JCRB1568
DR   Wikidata; Q54900002
RX   CelloPub=CLPUB00275;
RX   PubMed=12587840;
RX   PubMed=15884115;
RX   PubMed=15948244;
RX   PubMed=16475706;
RX   PubMed=20493868;
RX   PubMed=21871105;
RX   PubMed=29110582;
RX   PubMed=31077409;
RX   PubMed=35640676;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Southeast Asian; Thai.
CC   Doubling time: ~72 hours (PubMed=15948244).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=29110582; DepMap).
CC   Omics: Deep exome analysis.
ST   Source(s): DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 9
ST   D16S539: 10,11
ST   D18S51: 13
ST   D21S11: 31.2,33.2
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 10,15
ST   FGA: 22,25
ST   Penta D: 11
ST   Penta E: 9,11
ST   TH01: 8,9
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C36077; Hilar cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_99978; Klatskin tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=12587840;
RA   Panichakul T., Wanun T., Reutrakul V., Sirisinha S.;
RT   "Synergistic cytotoxicity and apoptosis induced in human
RT   cholangiocarcinoma cell lines by a combined treatment with tumor
RT   necrosis factor-alpha (TNF-alpha) and triptolide.";
RL   Asian Pac. J. Allergy Immunol. 20:167-173(2002).
//
RX   PubMed=15884115; DOI=10.3748/wjg.v11.i18.2748;
RA   Tepsiri N., Chaturat L., Sripa B., Namwat W., Wongkham S.,
RA   Bhudhisawasdi V., Tassaneeyakul W.;
RT   "Drug sensitivity and drug resistance profiles of human intrahepatic
RT   cholangiocarcinoma cell lines.";
RL   World J. Gastroenterol. 11:2748-2753(2005).
//
RX   PubMed=15948244; DOI=10.3748/wjg.v11.i22.3392;
RA   Sripa B., Leungwattanawanit S., Nitta T., Wongkham C.,
RA   Bhudhisawasdi V., Puapairoj A., Sripa C., Miwa M.;
RT   "Establishment and characterization of an opisthorchiasis-associated
RT   cholangiocarcinoma cell line (KKU-100).";
RL   World J. Gastroenterol. 11:3392-3397(2005).
//
RX   PubMed=16475706;
RA   Panichakul T., Intachote P., Wongkajornsilp A., Sripa B., Sirisinha S.;
RT   "Triptolide sensitizes resistant cholangiocarcinoma cells to
RT   TRAIL-induced apoptosis.";
RL   Anticancer Res. 26:259-265(2006).
//
RX   PubMed=20493868; DOI=10.1016/j.ijpara.2010.05.002;
RA   Yonglitthipagon P., Pairojkul C., Chamgramol Y., Mulvenna J.,
RA   Sripa B.;
RT   "Up-regulation of annexin A2 in cholangiocarcinoma caused by
RT   Opisthorchis viverrini and its implication as a prognostic marker.";
RL   Int. J. Parasitol. 40:1203-1212(2010).
//
RX   PubMed=21871105; DOI=10.1186/1476-4598-10-102;
RA   Obchoei S., Weakley S.M., Wongkham S., Wongkham C., Sawanyawisuth K.,
RA   Yao Q.-Z., Chen C.-Y.;
RT   "Cyclophilin A enhances cell proliferation and tumor growth of liver
RT   fluke-associated cholangiocarcinoma.";
RL   Mol. Cancer 10:102.1-102.15(2011).
//
RX   PubMed=29110582; DOI=10.1177/1010428317725925;
RA   Saensa-ard S., Leuangwattanawanit S., Senggunprai L., Namwat N.,
RA   Kongpetch S., Chamgramol Y., Loilome W., Khansaard W., Jusakul A.,
RA   Prawan A., Pairojkul C., Khantikeo N., Yongvanit P.,
RA   Kukongviriyapan V.;
RT   "Establishment of cholangiocarcinoma cell lines from patients in the
RT   endemic area of liver fluke infection in Thailand.";
RL   Tumor Biol. 39:1010428317725925-1010428317725925(2017).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//